AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35850771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume challenge (TVC) with pulse pressure variation (PPV) monitoring
Number of subjects: 58
Study 35850782 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX treatment
Number of subjects: 19
Study 35851282 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated strain assessment (GLS)
Number of subjects: 1095
Study 35851282 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated strain assessment (GCS)
Number of subjects: 1095
Study 35851282 — intervention group
Group type: COMPARATOR
Intervention: Manual strain assessment (GLS)
Number of subjects: 1095
Study 35851282 — intervention group
Group type: COMPARATOR
Intervention: Manual strain assessment (GCS)
Number of subjects: 1095
Study 35851282 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated functional analyses (GLS)
Number of subjects: 1095
Study 35851316 — intervention group
Group type: EXPERIMENTAL
Intervention: Second tertile of Lp(a) concentrations
Number of subjects: 3059
Study 35851316 — intervention group
Group type: EXPERIMENTAL
Intervention: Third tertile of Lp(a) concentrations
Number of subjects: 3059
Study 35851408 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP-ligand peptide (E5)
Number of subjects: 94
Study 35851408 — intervention group
Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 94
Study 35851408 — intervention group
Group type: COMPARATOR
Intervention: GERD patients
Number of subjects: 94
Study 35851430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week online singing intervention (Melodies for Mums - M4M)
Number of subjects: 120
Study 35852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy (Arm D)
Number of subjects: 106
Study 35852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with lenalidomide ± rituximab (Arm A)
Number of subjects: 106
Study 35852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with ibrutinib (Arm B)
Number of subjects: 106
Study 35852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with rituximab ± bendamustine (Arm C)
Number of subjects: 106
Study 35852004 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (monotherapy or combination)
Number of subjects: 106
Study 35852094 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) at 2 mA for 30 minutes daily for 4 months
Number of subjects: 8
Study 35852104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 35852104 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35852275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 12 weeks
Number of subjects: 70
Study 35852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraprocessed food intake (quartile 4 vs. 1)
Number of subjects: 1948
Study 35852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraprocessed food intake
Number of subjects: 1948
Study 35852425 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Number of subjects: 94
Study 35852425 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-US
Number of subjects: 94
Study 35852431 — intervention group
Group type: EXPERIMENTAL
Intervention: DCFPyL PET/CT in newly diagnosed prostate cancer (sample 1)
Number of subjects: 184
Study 35852431 — intervention group
Group type: EXPERIMENTAL
Intervention: DCFPyL PET/CT in biochemically recurrent prostate cancer (sample 2)
Number of subjects: 184
Study 35852544 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (specifically Random Forests)
Number of subjects: 3782
Study 35852544 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (using only the eight most important features)
Number of subjects: 3782
Study 35852544 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (general prediction)
Number of subjects: 3782
Study 35852619 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DEP regimen as induction therapy
Number of subjects: 28
Study 35852656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (4,000 IU or 2,000 IU per day)
Number of subjects: 18
Study 35852656 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 35852831 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based ASD diagnosis aid integrated into the ECHO Autism STAT diagnosis model
Number of subjects: 41
Study 35852839 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-920, a topical ocular anesthetic
Number of subjects: 0
Study 35852876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 35853003 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental T2* measurements using BOLD-MRI
Number of subjects: 316
Study 35853003 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental T2* percentile
Number of subjects: 316
Study 35853188 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (qHPV; HPV6/11/16/18)
Number of subjects: 3403
Study 35853530 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipod® 5 Automated Insulin Delivery (AID) System
Number of subjects: 115
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line (1L) erlotinib
Number of subjects: 120
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line (1L) afatinib
Number of subjects: 120
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line (1L) gefitinib
Number of subjects: 120
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for T790M mutation after progression on 1L treatment
Number of subjects: 120
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line (2L) treatment with osimertinib
Number of subjects: 120
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world progression free survival on 1L EGFR TKIs
Number of subjects: 120
Study 35853681 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival on 1L EGFR TKIs
Number of subjects: 120
Study 35853728 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Erythropoietin for Protection of Infant Renal Disease (REPAIReD) study
Number of subjects: 832
Study 35853728 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 832
Study 35853745 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant WWE
Number of subjects: 241
Study 35853863 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-MERS-S booster vaccination
Number of subjects: 0
Study 35853972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led health dialogue focusing on lifestyle habits, anthropometric measurements, and blood samples.
Number of subjects: 64
Study 35853994 — intervention group
Group type: EXPERIMENTAL
Intervention: ERY974 at a starting dose of 3.0 ng/kg
Number of subjects: 0
Study 35853994 — intervention group
Group type: EXPERIMENTAL
Intervention: ERY974 at 4.9 ng/kg
Number of subjects: 0
Study 35853994 — intervention group
Group type: EXPERIMENTAL
Intervention: ERY974 at 0.1 μg/kg
Number of subjects: 0
Study 35853994 — intervention group
Group type: EXPERIMENTAL
Intervention: ERY974 at 3.2 ng/kg
Number of subjects: 0
Study 35854086 — intervention group
Group type: EXPERIMENTAL
Intervention: SharePR parent-report measure of caregiver-infant reading quality
Number of subjects: 207
Study 35854137 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) injection
Number of subjects: 63
Study 35854274 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiological assessments in patients with GACI
Number of subjects: 19
Study 35854274 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiometric configurations
Number of subjects: 19
Study 35854274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial CT imaging
Number of subjects: 19
Study 35854274 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent episodes of otitis media (ROM)
Number of subjects: 19
Study 35854275 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive liver stiffness measurement (LSM) by vibration-controlled transient elastography
Number of subjects: 30000
Study 35854275 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic evaluation
Number of subjects: 30000
Study 35854296 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer Matters programme (including needs assessment, educational resources, tele-support, and training courses)
Number of subjects: 550
Study 35854296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-support provided to caregivers reporting high burden (69 caregivers)
Number of subjects: 550
Study 35854296 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training courses attended by 252 caregivers
Number of subjects: 550
Study 35854318 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to moral distress during the COVID-19 pandemic
Number of subjects: 313
Study 35854318 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of inappropriate care
Number of subjects: 313
Study 35854318 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients dying with dignity
Number of subjects: 313
Study 35854318 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care practice changes during the pandemic
Number of subjects: 313
Study 35854321 — intervention group
Group type: EXPERIMENTAL
Intervention: ATLAS 2030 gait exoskeleton, used for nine sessions bi-weekly of 60 min each.
Number of subjects: 3
Study 35854324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental distress during TB investigation and treatment
Number of subjects: 80
Study 35854324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental distress symptoms
Number of subjects: 80
Study 35854324 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual level drivers of mental distress
Number of subjects: 80
Study 35854324 — intervention group
Group type: EXPERIMENTAL
Intervention: Social, economic and health system level drivers of mental distress
Number of subjects: 80
Study 35854324 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic stress of poverty
Number of subjects: 80
Study 35854324 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures to support TB patients
Number of subjects: 80
Study 35854330 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL-HHT questionnaire (24 items measuring 6 domains of QOL)
Number of subjects: 643
Study 35854375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention within the KUPA project
Number of subjects: 39
Study 35854388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-DLB group (148 patients)
Number of subjects: 892
Study 35854388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-DLB group
Number of subjects: 892
Study 35854388 — intervention group
Group type: COMPARATOR
Intervention: NS group (control)
Number of subjects: 892
Study 35854388 — intervention group
Group type: COMPARATOR
Intervention: 1S group (control)
Number of subjects: 892
Study 35854392 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Internet-delivered exposure treatment
Number of subjects: 33
Study 35854467 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI/MRCP screening
Number of subjects: 75
Study 35854467 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 75
Study 35854467 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 75
Study 35854467 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety assessment
Number of subjects: 75
Study 35854467 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 75
Study 35854937 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA status (measured by RBC DHA)
Number of subjects: 0
Study 35854937 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA intake (dietary)
Number of subjects: 0
Study 35854937 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA intake
Number of subjects: 0
Study 35854939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' complementary feeding support (≥2 actions)
Number of subjects: 495
Study 35854939 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' perspectives of mothers' autonomy
Number of subjects: 495
Study 35854939 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' perspectives of fathers' complementary feeding support
Number of subjects: 495
Study 35855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcoidosis patients with mild OSA (AHI ≥ 5 events/h)
Number of subjects: 71
Study 35855534 — intervention group
Group type: COMPARATOR
Intervention: Matched controls with mild OSA (AHI ≥ 5 events/h)
Number of subjects: 71
Study 35855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of mild OSA in sarcoidosis patients
Number of subjects: 71
Study 35855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of OSA on sleepiness and fatigue in sarcoidosis
Number of subjects: 71
Study 35855534 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for OSA in sarcoidosis patients
Number of subjects: 71
Study 35855645 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 409
Study 35856081 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Isatuximab (experimental arm)
Number of subjects: 30
Study 35856081 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib (control arm)
Number of subjects: 30
Study 35856081 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-control design (integrating historical trial data)
Number of subjects: 30
Study 35856671 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-tilmanocept uptake in PWH
Number of subjects: 30
Study 35856671 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncalcified aortic plaque volume in PWH
Number of subjects: 30
Study 35856671 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic levels of caspase-1 in PWH
Number of subjects: 30
Study 35856671 — intervention group
Group type: EXPERIMENTAL
Intervention: CD14-CD16+ monocytes in PWH
Number of subjects: 30
Study 35856671 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ T cells in PWH
Number of subjects: 30
Study 35856671 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+/CD8+ T-cell ratio in PWH
Number of subjects: 30
Study 35856836 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater morning actigraphic physical activity from 9:00 to 12:00
Number of subjects: 134
Study 35856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater afternoon activity from 12:00 to 15:00
Number of subjects: 134
Study 35856908 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon physical activity from 12:00 to 15:00
Number of subjects: 134
Study 35857060 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment for T2DM
Number of subjects: 1798
Study 35857365 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 982
Study 35857405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day, orally, 2 weeks on and 1 week off, every 3 weeks) plus Toripalimab (240 mg, intravenously over 60 minutes, once every 2 weeks)
Number of subjects: 29
Study 35857405 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus Toripalimab
Number of subjects: 29
Study 35857579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal delivery of tremelimumab (2 to 20 mg)
Number of subjects: 13
Study 35857660 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT180a (verbrinacogene setparvovec) gene therapy at varying doses (3.84×10^11 vg/kg) with glucocorticoids and/or tacrolimus for immunosuppression
Number of subjects: 10
Study 35857660 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT180a (verbrinacogene setparvovec) gene therapy
Number of subjects: 10
Study 35858168 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study 35858168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35858254 — intervention group
Group type: EXPERIMENTAL
Intervention: VR physical exercises at home for 6 weeks
Number of subjects: 48
Study 35858254 — intervention group
Group type: EXPERIMENTAL
Intervention: VR mental exercises through applications
Number of subjects: 48
Study 35858254 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exercises (physical, relaxing, and cognitive)
Number of subjects: 48
Study 35858254 — intervention group
Group type: EXPERIMENTAL
Intervention: VR exercises
Number of subjects: 48
Study 35858373 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol)
Number of subjects: 80
Study 35858373 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP prophylaxis
Number of subjects: 80
Study 35858373 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP
Number of subjects: 80
Study 35858479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention (CP)
Number of subjects: 284
Study 35858479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CP intervention)
Number of subjects: 284
Study 35858538 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 16-24 years
Number of subjects: 16518
Study 35858538 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 25-34 years
Number of subjects: 16518
Study 35858538 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 35-44 years
Number of subjects: 16518
Study 35858538 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age 45-54 years
Number of subjects: 16518
Study 35858586 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-MERS-S vaccine (modified vaccinia virus Ankara-based vaccine) administered on days 0 and 28 with a late booster vaccination at 12 ± 4 months.
Number of subjects: 0
Study 35858774 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal atrial fibrillation (PAF)
Number of subjects: 417
Study 35858774 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers
Number of subjects: 417
Study 35858774 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 417
Study 35858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-first wave (June-August 2020)
Number of subjects: 1000
Study 35858775 — intervention group
Group type: EXPERIMENTAL
Intervention: April-June 2021
Number of subjects: 1000
Study 35858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority ethnic groups
Number of subjects: 1000
Study 35858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Children <10 years
Number of subjects: 1000
Study 35858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall seropositive participants
Number of subjects: 1000
Study 35858775 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants aged 15-18 years
Number of subjects: 1000
Study 35858849 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT) using TheraSpheres
Number of subjects: 24
Study 35858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb functional index-Urdu (ULFI-U)
Number of subjects: 250
Study 35858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric pain rating scale (NPRS)
Number of subjects: 250
Study 35858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Disability of arm, shoulder, and hand (QuickDash)
Number of subjects: 250
Study 35858863 — intervention group
Group type: EXPERIMENTAL
Intervention: Health survey (SF-12)
Number of subjects: 250
Study 35858894 — intervention group
Group type: EXPERIMENTAL
Intervention: LIQOSEAL
Number of subjects: 228
Study 35858894 — intervention group
Group type: COMPARATOR
Intervention: FDA-approved PEG sealant
Number of subjects: 228
Study 35858899 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-treated COVID-19 patients
Number of subjects: 213
Study 35858899 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-treated COVID-19 patients with more than 12 years of education
Number of subjects: 213
Study 35858989 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the nucleus accumbens (NAc)
Number of subjects: 6
Study 35859001 — intervention group
Group type: EXPERIMENTAL
Intervention: Late fetal demise patients assessed at 15 days
Number of subjects: 100
Study 35859001 — intervention group
Group type: EXPERIMENTAL
Intervention: Late fetal demise patients assessed at one month
Number of subjects: 100
Study 35859001 — intervention group
Group type: EXPERIMENTAL
Intervention: Late fetal demise patients assessed at three months
Number of subjects: 100
Study 35859001 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with PTSD symptoms
Number of subjects: 100
Study 35859065 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based exercise program delivered by a patient organisation
Number of subjects: 35
Study 35860245 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cells (BM-MSCs)
Number of subjects: 32
Study 35860245 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy with dexamethasone)
Number of subjects: 32
Study 35860581 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiation therapy (3D-CRT)
Number of subjects: 116
Study 35860581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no arrhythmia)
Number of subjects: 116
Study 35860587 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 551
Study 35860587 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 551
Study 35860743 — intervention group
Group type: EXPERIMENTAL
Intervention: 1273-mRNA
Number of subjects: 193
Study 35860743 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2-mRNA
Number of subjects: 193
Study 35860743 — intervention group
Group type: COMPARATOR
Intervention: No booster vaccination
Number of subjects: 193
Study 35860752 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM)
Number of subjects: 584
Study 35860752 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 584
Study 35860752 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate circulatory failure
Number of subjects: 584
Study 35860752 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe circulatory failure
Number of subjects: 584